Skip to main content
. Author manuscript; available in PMC: 2014 Nov 14.
Published in final edited form as: Immunity. 2013 Oct 31;39(5):874–884. doi: 10.1016/j.immuni.2013.08.039

Figure 4. The ATM-dependent protection of epirubicin against severe sepsis relies on the induction of autophagy.

Figure 4

(a) Survival of Lc3b+/+ and Lc3b−/− animals subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as in fig 1. (b) LDH, CK, ALT, urea and (c) TNF, IL-1β and IL-6 plasma concentrations in Lc3b−/− animals 24 hours after mock CLP (S) (n=2) or CLP followed by treatment with PBS (C+P) (n=4) or epirubicin (C+E) (n=7) as in (2b). Results shown represent arithmetic means ± SEM from triplicate readings per animal. ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (a), unpaired t test for (b) and (c)). See also Figure S4.